DIAPH3 predicts survival of patients with <i>MGMT</i>-methylated glioblastoma

DIAPH3 predicts survival of patients with <i>MGMT</i>-methylated glioblastoma

<h3>Background</h3><p dir="ltr">Glioblastoma is one of the most aggressive primary brain tumors, with a poor outcome despite multimodal treatment. Methylation of the <i>MGMT</i> promoter, which predicts the response to temozolomide, is a well-established progn...

Full description

Saved in:
Bibliographic Details
Main Author: Georges Chehade (18007084) (author)
Other Authors: Nady El Hajj (686554) (author), Mohamed Aittaleb (18007087) (author), Maisa I. Alkailani (15070764) (author), Yosra Bejaoui (8552574) (author), Asma Mahdi (18007090) (author), Arwa A. H. Aldaalis (18007093) (author), Michael Verbiest (532371) (author), Julie Lelotte (9223075) (author), Nuria Ruiz-Reig (14434026) (author), Irene Durá (18007096) (author), Christian Raftopoulos (843696) (author), Nicolas Tajeddine (18007099) (author), Fadel Tissir (245153) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Clinical sciences
Neurosciences
Oncology and carcinogenesis
diaphanous formin
glioblastoma
mDia2
O(6)-methylguanine-DNA methyltransferase
MGMT methylation
survival
The Cancer Genome Atlas
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items